Cryptocaryone, a Natural Dihydrochalcone, Induces Apoptosis in Human Androgen Independent Prostate Cancer Cells by Death Receptor Clustering in Lipid Raft and Nonraft Compartments

Journal of Urology

Volumn 183, Issue 6, 2010, Pages 2409-2418

  Chen, Yi Cheng ^a   Kung, Fan Lu ^a   Tsai, Ian Lih ^b   Chou, Tsung Hsien ^b   Chen, Ih Sheng ^b   Guh, Jih Hwa ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

caspase 8; membrane microdomains; prostate; prostatic neoplasms; receptors, death domain

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; CRYPTOCARYONE; DEATH RECEPTOR; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; HLA DR4 ANTIGEN; HLA DR5 ANTIGEN; METHYL BETA CYCLODEXTRIN; PROCASPASE 8; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG TARGETING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IC 50; IMMUNOFLUORESCENCE; LIPID RAFT; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANDROGENS; APOPTOSIS; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; MALE; MEMBRANE MICRODOMAINS; PROSTATIC NEOPLASMS; PYRONES; RECEPTORS, DEATH DOMAIN; TUMOR CELLS, CULTURED;

EID: 77951877744     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.01.065     Document Type: Article

References (30)

1. Wajant H., Johannes F.J., Haas E., et al. Dominant-negative FADD inhibits TNFR60-, Fas/Apo1- and TRAIL-R/Apo2-mediated cell death but not gene induction. Curr Biol 8 (1998) 113
2. Bao Q., and Shi Y. Apoptosome: a platform for the activation of initiator caspases. Cell Death Differ 14 (2007) 56
3. Adams J.M., and Cory S. Apoptosomes: engines for caspase activation. Curr Opin Cell Biol 14 (2002) 715
4. Hajra K.M., and Liu J.R. Apoptosome dysfunction in human cancer. Apoptosis 9 (2004) 691
5. Ionov Y., Yamamoto H., Krajewski S., et al. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A 97 (2000) 10872
6. Kondo S., Shinomura Y., Miyazaki Y., et al. Mutations of the bak gene in human gastric and colorectal cancers. Cancer Res 60 (2000) 4328
7. Sastry K.S., Karpova Y., Prokopovich S., et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem 282 (2007) 14094
8. Nelson J.B., Udan M.S., Guruli G., et al. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 7 (2005) 631
9. Marone M., Scambia G., Mozzetti S., et al. Bcl-2, bax, bcl-XL, and bcl-XS expression in normal and neoplastic ovarian tissues. Clin Cancer Res 4 (1998) 517
10. Schwartz P.S., Manion M.K., Emerson C.B., et al. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol Cancer Ther 6 (2007) 2073
11. Tsuruo T., Naito M., Tomida A., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 94 (2003) 15
12. Buchsbaum D.J., Zhou T., and Lobuglio A.F. TRAIL receptor-targeted therapy. Future Oncol 2 (2006) 493
13. Kurbanov B.M., Geilen C.C., Fecker L.F., et al. Efficient TRAIL-R1/DR4-mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 125 (2005) 1010
14. de Jong S., Timmer T., Heijenbrok F.J., et al. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 20 (2001) 51
15. Dumontet V., Gaspard C., Van Hung N., et al. New cytotoxic flavonoids from Cryptocarya infectoria. Tetrahedron 57 (2001) 6189
16. Chiang P.C., Kung F.L., Huang D.M., et al. Induction of Fas clustering and apoptosis by coral prostanoid in human hormone-resistant prostate cancer cells. Eur J Pharmacol 542 (2006) 22
17. Gajate C., and Mollinedo F. Edelfosine and perifosine induce selective apoptosis in multiple myeloma by recruitment of death receptors and downstream signaling molecules into lipid rafts. Blood 109 (2007) 711
18. Cheng P.C., Dykstra M.L., Mitchell R.N., et al. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J Exp Med 190 (1999) 1549
19. Mollinedo F., and Gajate C. Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat 9 (2006) 51
20. Bionda C., Athias A., Poncet D., et al. Differential regulation of cell death in head and neck cell carcinoma through alteration of cholesterol levels in lipid rafts microdomains. Biochem Pharmacol 75 (2008) 761
21. Gniadecki R. Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosis. Biochem Biophys Res Commun 320 (2004) 165
22. Hendrikse N.H. Monitoring interactions at ATP-dependent drug efflux pumps. Curr Pharm Des 6 (2000) 1653
23. Yang T., Buchan H.L., Townsend K.J., et al. Mcl-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 166 (1996) 523
24. Michels J., Johnson P.W., and Packham G. Mcl-1. Int J Biochem Cell Biol 37 (2005) 267
25. Dykstra M., Cherukuri A., Sohn H.W., et al. Location is everything: lipid rafts and immune cell signaling. Annu Rev Immunol 21 (2003) 457
26. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 1 (2000) 31
27. Gajate C., and Mollinedo F. The antitumor ether lipid ET-18-OCH3 induces apoptosis through translocation and capping of Fas/CD95 into membrane rafts in human leukemic cells. Blood 98 (2001) 3860
28. Huang Y., and Sheikh M.S. TRAIL death receptors and cancer therapeutics. Toxicol Appl Pharmacol 224 (2007) 284
29. Cretney E., Takeda K., and Smyth M.J. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway. Int J Biochem Cell Biol 39 (2007) 280
30. de Vries E.G., Timmer T., Mulder N.H., et al. Modulation of death receptor pathways in oncology. Drugs Today (Barc) 39 suppl. (2003) 95